LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Flu vaccines: Assessing the patent and innovation ...

With winter in full swing, no doubt many of us will have come down with flu...

Read More

SPC you later to drug-device combinations

On 25 October 2018 the Court of Justice of the European Union (CJEU) handed...

Read More

Investing in Early-Stage Innovation: Q&A with Sano...

How are established investors working to foster innovation in today’s biote...

Read More

LSX World Congress 2019 fast approaches

On 5-6 February 2019, international life sciences investors, C-level execut...

Read More

Addex prepares PD-LID programme for 2019 Phase 3 r...

Key findings: Switzerland-based Addex Therapeutics is preparing its lead ca...

Read More

Life science leaders to address strategic company ...

Senior executives and investors in the life sciences sector will convene in...

Read More

Investorview: Propelling life science innovation f...

Denmark’s Novo Seeds was established in 2007 in order to identify promising...

Read More

Gates Foundation funding for DelSiTech’s silica-ba...

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More

€79m Series C pushes Galecto Biotech’s pipeline in...

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Add Your Response